Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1606-1609

  Barnes, Theresa ^a   Gliddon, Angela ^b   Doré, Caroline J ^c   Maddison, Peter ^b   Moots, Robert J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Pulmonary artery hypertension; Systemic sclerosis; Von Willebrand factor; VWF

Indexed keywords

BIOLOGICAL MARKER; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; FEMALE; FINGER ULCER; FORCED VITAL CAPACITY; GLOMERULUS FILTRATION RATE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PULMONARY HYPERTENSION; RANKIN SCALE; RAYNAUD PHENOMENON; RISK ASSESSMENT; SYSTEMIC SCLEROSIS;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; LOGISTIC MODELS; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY ARTERY; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND FACTOR;

EID: 84865344315     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes068     Document Type: Article

References (16)

1. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008;34: 41-55, vi.
2. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-65.
3. Herrick AL, Illingworth K, Blann A et al. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
4. Scheja A, Eskilsson J, Akesson A, Wollheim FA. Inverse relation between plasma concentration of von Willebrand factor and CrEDTA clearance in systemic sclerosis. J Rheumatol 1994;21:639-42.
5. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-54.
6. Hachulla I, Carpentier P, Gressin V et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology 2009;48:304-8.
7. McLaughlin VV. Survival in patients with pulmonary artery hypertension. Eur J Clin Invest 2006;36(Suppl 3):10-5.
8. Vachiery JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18:162-9.
9. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
10. Medsger TA, Silman A, Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
11. Jenkins PV, O'Donnell J. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006;46:1836-44.
12. Scheja A, Akesson A, Geborek P et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001;3: 178-82.
13. Geggel RL, Carvalho AC, Hoyer LW, Reid LM. von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987;135:294-9.
14. Rossi R, Nuzzo A, Lattanzi A, Coppi F, Modena MG. Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulm Pharmacol Ther 2008;21: 172-7.
15. Furukawa S, Yasuda S, Amengual O et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 2006;65: 1118-20.
16. Sweiss NJ, Hushaw L, Thenappan T et al. Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep 2010;12:8-18.